While rare, it appears that many different TKIs share the ability to induce PRES, and that VEGF antagonism may play a role, such that clinicians should be aware of this potential side effect when prescribing these novel medications. The gene discussed is VEGFA; the disease is Posterior Leukoencephalopathy Syndrome.